#Liquid Biopsy Market growth

[healthcaremarketanalysis]

Liquid Biopsy market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a latest report published by MarketsandMarkets™.

With the increasing incidence & prevalence of cancer worldwide, there's a growing need for effective methods of early detection, therapy selection, monitoring treatment response, and detecting disease recurrence. Liquid biopsies provide a promising solution by enabling clinicians to detect and analyze cancer-related biomarkers more easily and frequently than traditional tissue biopsies. The burgeoning adoption and recognition of liquid biopsy's advantages over traditional biopsy methods are also propelling a robust evolution in liquid biopsy products and services. However, lack of desired sensitivity and specificity in certain liquid biopsy products is likely to restrain the growth of the market.

[mitalipingale]

The Liquid Biopsy Market in 2023 is US$ 5.1 billion, and is expected to reach US$ 19.84 billion by 2031 at a CAGR of 18.52%.

[marketdevelopment]

Liquid Biopsy Market Latest Innovations, Drivers and Industry Status 2023 to 2030

The Global Liquid Biopsy Market size is expected to grow from USD 1.59 billion in 2022 to USD 7.02 billion by 2030, at a CAGR of 20.4% during the forecast period (2023-2030).

A liquid biopsy is a minimally invasive diagnostic procedure that involves analyzing various biomarkers (such as circulating tumor cells, cell-free DNA, exosomes, and other nucleic acids) found in bodily fluids like blood, urine, or saliva. It's primarily used for the detection and monitoring of diseases, particularly cancer.

Advances in technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and digital PCR have greatly enhanced the sensitivity and specificity of liquid biopsy tests, enabling more accurate detection and monitoring of diseases.

Liquid biopsies have gained particular attention in the field of oncology for early cancer detection, monitoring treatment response, and detecting resistance mutations. They offer a non-invasive alternative to tissue biopsies and can provide real-time information on tumor dynamics.

While oncology remains the primary focus of liquid biopsy applications, researchers and companies have been exploring its potential in other areas such as prenatal testing, infectious disease diagnostics, transplant monitoring, and autoimmune disease detection.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @

https://introspectivemarketresearch.com/request/16300

Updated Version 2024 is available our Sample Report May Includes the:

Scope For 2024

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Worldwide Market Reports

Leading players involved in the Liquid Biopsy Market include:

Agilent Technologies (United States), Bio-Rad Laboratories, Inc. (United States), Beckman Coulter(United States), Illumina (United States), PerkinElmer (United States), Becton, Dickinson and Company (BD) (United States), Johnson & Johnson (United States), Abbott Laboratories (United States), Cancer Genetics, Inc. (United States), Myriad Genetics, Inc. (United States) 

Moreover, the report includes significant chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis which help to understand the market direction and movement in the current and upcoming years. 

If You Have Any Query Liquid Biopsy Market Report, Visit:

https://introspectivemarketresearch.com/inquiry/16300

Segmentation of Liquid Biopsy Market:

By Cancer Type

Lung

Breast

Liver

By Circulating Biomarker

Circulating Tumor DNA

Circulating Tumor Cells

By End-User

Hospitals

Laboratories

Government Research Centre

By Regions: -

North America (US, Canada, Mexico)

Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

South America (Brazil, Argentina, Rest of SA)

Key Reasons To Invest In Liquid Biopsy Market Report:

To provide a complete structure and a basic overview of the Liquid Biopsy market.

To provide insights into important Liquid Biopsy aspects such as growth trajectory, CAGR value, market share, and revenue analysis.

Assess growth opportunities, threats, market drivers, and associated risks.

To understand the Liquid Biopsy market competition by analysing the top business people along with market profiles, import/export details, revenue, profit, and market shares.

Indicate pricing structure, import/export details, supply chain analysis, SWOT analysis to facilitate key decision-making process.

Analysing emerging Liquid Biopsy market segments and sub-segments to drive ultimate growth, investment analysis, and future growth opportunities.

Understand sources of knowledge, intended research methodology, and important conclusions.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Acquire This Reports: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16300

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assisting our clients to grow and have a successful impact on the market. Our team at IMR is ready to assist our clients to flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, that specializes in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyse extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.

Contact us:

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1047

Email: sales@introspectivemarketresearch.com

[aarunresearcher]

The United States liquid biopsy market is experiencing rapid growth and significant advancements as a groundbreaking diagnostic tool in the field of cancer detection and monitoring. This minimally invasive technique involves the analysis of blood or other bodily fluids to identify genetic material or biomarkers originating from tumors, presenting a paradigm shift in cancer diagnostics. 

[marketinsight1234]

Liquid Biopsy Market Size-Share, Growth Factors, Forecast 2023-2030

The Global Liquid Biopsy Market size is expected to grow from USD 1.59 billion in 2022 to USD 7.02 billion by 2030, at a CAGR of 20.4% during the forecast period (2023-2030).

The liquid biopsy market has witnessed substantial growth in recent years, driven by advancements in cancer diagnostics and personalized medicine. Unlike traditional biopsy methods, liquid biopsy offers a non-invasive approach to detect and monitor various conditions, particularly cancer, by analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers present in blood or other bodily fluids. The market's growth is propelled by the rising incidence of cancer, increased emphasis on early detection, and the growing adoption of precision medicine.

Request Sample Copy@:

https://introspectivemarketresearch.com/request/16300

Leading Key Players Covered Liquid Biopsy Market: -

F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (the US), Guardant Health Inc. (the US), BIOCEPT Inc. (the US), Illumina Inc. (the US), Angle plc (UK), Oncimmune(UK), Lucence health Inc. (US), FreenomeHoldings Inc. (US) and Other Major Players.

Market Driver:

One key driver fueling the liquid biopsy market is the demand for less invasive and more accessible diagnostic methods. Traditional biopsies are often invasive, requiring surgical procedures that can be uncomfortable and carry potential risks. Liquid biopsies, on the other hand, offer a minimally invasive alternative, reducing patient discomfort and complications. This non-invasiveness enhances patient compliance and enables the monitoring of disease progression over time. As a result, liquid biopsies are increasingly becoming the preferred choice for cancer screening and monitoring, contributing significantly to the market's expansion.

Market Opportunity:

A significant market opportunity lies in the integration of liquid biopsy technologies with artificial intelligence (AI) and machine learning (ML) algorithms. The vast amount of data generated by liquid biopsy tests can be effectively analyzed and interpreted using these advanced technologies. AI and ML can enhance the accuracy of diagnosis, identify subtle biomarker patterns, and provide valuable insights for personalized treatment strategies. Integrating liquid biopsy with AI not only improves the diagnostic capabilities but also opens avenues for predictive and preventive healthcare. This convergence presents a promising opportunity for companies to develop innovative solutions that combine molecular diagnostics with cutting-edge data analytics.

Segmentation of Liquid Biopsy Market: -

By Cancer Type         

By Circulating Biomarker     

By End-User   

If You Have Any Queries Regarding Liquid Biopsy Market, Please Visit:

https://introspectivemarketresearch.com/inquiry/16300

Owning our reports (For More, Buy Our Report) will help you solve the following issues:

1. Uncertainty about the future?

Our research and insights help our clients to foresee upcoming revenue pockets and growth areas. This helps our clients to invest or divest their resources.

2. Understanding market sentiments?

It is imperative to have a fair understanding of market sentiments for a strategy. Our insights furnish you with a hawk-eye view on market sentiment. We keep this observation by engaging with Key Opinion Leaders of a value chain of each industry we track.

3. Understanding the most reliable investment centers?

Our research ranks investment centers of the market by considering their returns, future demands, and profit margins. Our clients can focus on the most prominent investment centers by procuring our market research.

4. Evaluating potential business partners?

Our research and insights help our clients in identifying compatible business partners.

Acquire This Report: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16300

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to helping our clients grow and successfully impact the marketplace. Our team at IMR is ready to help our clients grow their businesses by offering strategies to achieve success and monopoly in their respective fields. We are a global market research company, specializing in the use of big data and advanced analytics to gain a broader picture of market trends. We help our customers to think differently and build a better tomorrow for all of us. As a technology-driven research company, we consider extremely large data sets to uncover deeper insights and provide conclusive consulting. We don't just provide intelligence solutions, we help our clients achieve their goals.

Contact us:

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1049

Email: sales@introspectivemarketresearch.com

[vijukumar]

Navigating Precision: Unveiling the Dynamics of the Biopsy Devices Market

In the realm of diagnostic innovation, the Biopsy Devices Market stands at the forefront, revolutionizing the way medical professionals identify and treat various diseases. This blog will explore the market landscape, including key segments like the Liquid Biopsy Market and Breast Biopsy Devices Market, shedding light on the demand, growth, and the role of cutting-edge technology in this critical field.

Biopsy Devices Market Overview

Market Size and Growth

Biopsy Devices Market size exceeded USD 2 billion in 2022 and is anticipated to depict over 6% CAGR through 2023-2032. Increasing prevalence of breast cancer along with strong awareness about innovative diagnostic equipment availability will boost the global industry growth.

Market Revenue and Share

In terms of revenue, the market reached USD 2.3 billion in 2022, showcasing a robust financial outlook. Key players in the industry continue to vie for a substantial market share by introducing advanced biopsy technologies.

Market Suppliers and Manufacturers

A network of suppliers and manufacturers fuels the biopsy devices ecosystem. With a growing demand for biopsy tools, suppliers play a pivotal role in ensuring a steady supply chain for manufacturers to meet the market needs.

Key Segments in Biopsy Devices Market

Liquid Biopsy Market

A paradigm shift in diagnostics, the Liquid Biopsy Market is gaining prominence. This non-invasive approach allows for the detection of circulating tumor cells and nucleic acids, providing valuable insights into cancer progression and treatment response.

Breast Biopsy Devices Market

Breast cancer remains a significant global health concern. The Breast Biopsy Devices Market, valued at USD 475 million in 2022, is driven by the imperative need for accurate and early diagnosis in breast cancer cases.

Biopsy Devices Market Trends

Smart Biopsy Devices

The integration of smart technologies is a notable trend. Smart Biopsy Devices, equipped with artificial intelligence and real-time imaging, enhance precision and efficiency in sample collection, diagnosis, and treatment planning.

Rising Demand

With an increasing awareness of preventive healthcare and early diagnosis, there is a rising demand for biopsy devices. Patients and healthcare professionals alike are recognizing the importance of timely and accurate diagnostic interventions.

Smart Biopsy Devices Market: A Closer Look

The Smart Biopsy Devices Market is gaining traction, projected to reach USD 1.2 billion by 2025. These intelligent devices not only streamline the biopsy process but also enhance diagnostic accuracy, ultimately improving patient outcomes.

Conclusion

The Biopsy Devices Market, with its diverse segments and technological advancements, plays a pivotal role in modern healthcare. As the demand for accurate diagnostic tools continues to surge, the market is poised for sustained growth. The integration of smart technologies and the expansion of liquid biopsy applications further underscore the transformative potential of biopsy devices in shaping the future of medical diagnostics.

[futuretonext]

The EMEA Liquid Biopsy Market is projected to grow at a CAGR of around 13.98% during the forecast period, 2023-28. The market noticed consistent growth since the past few years, owing to the increasing prevalence of cancer patients coupled with a surge in demand for minimally invasive & fast diagnostic tests for detection. The rising prevalence of cancer has affected patients in the EMEA region, owing to the sedentary lifestyle, harmful carcinogenic elements in the environment, etc. According to the World Health Organisation (WHO), there were around 4 million cancer cases in Europe in 2020, of which nearly 2.4 million cases were in men & over 2.1 million in women.

[businessintelligenceinsightsblog]

As per Business Intelligence Insights (BII) study, the global Liquid Biopsy Market attained revenue growth of USD 2394.10 million in 2021 and it is projected to reach around USD 6365.03 million by 2028, growing at a 17.70 % CAGR.

[insightfulblogz]

Cancer Biomarkers Market Growth, Industry Trends, Manufacturers, and Forecast by 2032

Cancer biomarkers are biological molecules that serve as indicators of cancer presence, progression, and response to treatment. These biomarkers can be found in blood, urine, tissue, or other bodily fluids, and they provide critical information that helps in diagnosing, monitoring, and managing cancer. Biomarkers play a pivotal role in understanding the molecular makeup of cancer, allowing for the identification of specific genetic mutations or protein expressions associated with various types of cancer. This enables healthcare providers to make more accurate diagnoses and personalize treatment plans based on the individual’s specific biomarker profile. Some of the most common cancer biomarkers include HER2 in breast cancer, PSA (prostate-specific antigen) in prostate cancer, and EGFR (epidermal growth factor receptor) in lung cancer.

The advent of cancer biomarkers has revolutionized oncology, facilitating early detection of cancers when they are more treatable. These biomarkers not only help in identifying cancers at an early stage, but they also provide information about the likely aggressiveness of the disease and how well the patient may respond to certain therapies. Moreover, cancer biomarkers are critical in monitoring the efficacy of ongoing treatments, detecting recurrence, and determining the prognosis. The growing use of biomarkers has paved the way for personalized cancer therapies, where treatment is tailored to the genetic profile of both the patient and the tumor. As research continues, new and more sophisticated biomarkers are being discovered, offering hope for improved cancer detection, treatment, and survival outcomes.

The cancer biomarkers market Size was valued at USD 22 billion in 2023, and is expected to reach USD 58.12 billion by 2032, and grow at a CAGR of 11.4% over the forecast period 2024-2032.

Future Growth of Cancer Biomarkers

Increasing adoption of liquid biopsy techniques, which use blood samples to detect cancer biomarkers, for early detection and non-invasive monitoring.

Growing demand for personalized and targeted cancer therapies driven by advancements in genomic and molecular profiling.

Expansion of biomarker-based diagnostic tests for cancers that are currently underdiagnosed or difficult to detect, such as pancreatic and ovarian cancer.

Integration of artificial intelligence and machine learning into biomarker analysis to improve diagnostic accuracy and speed.

Rising investments in research to discover novel biomarkers, particularly for rare or hard-to-diagnose cancers.

Enhanced regulatory frameworks supporting the approval and commercialization of biomarker-based diagnostic tests.

Increasing use of biomarkers for the development of companion diagnostics to guide treatment decisions for specific cancer therapies.

Greater collaboration between pharmaceutical companies, biotechnology firms, and academic institutions to accelerate biomarker discovery and validation.

Emerging Trends in Cancer Biomarkers

The field of cancer biomarkers is experiencing significant advancements driven by the rise of liquid biopsy technology. Liquid biopsies enable the detection of cancer biomarkers from blood, urine, or other bodily fluids, providing a less invasive and more convenient alternative to traditional biopsy methods. This trend is expected to greatly impact early cancer detection, as liquid biopsies allow for the identification of biomarkers in the earliest stages of the disease, even before the onset of symptoms. Another emerging trend is the increased focus on multi-omics approaches, where genomic, proteomic, and metabolomic data are integrated to identify a broader range of biomarkers that can be used for diagnosis, prognosis, and treatment monitoring. This approach is helping to identify biomarkers that were previously undetectable and offers a more comprehensive understanding of cancer biology. Additionally, advancements in artificial intelligence (AI) are enhancing the analysis of biomarker data, allowing for quicker and more accurate identification of relevant biomarkers, thus improving clinical outcomes.

Applications of Cancer Biomarkers

Cancer biomarkers are used in a variety of ways across the oncology landscape. One of the primary applications is in early cancer detection, where biomarkers help to identify the presence of cancer before clinical symptoms appear. This is especially valuable in cancers like colorectal, breast, and lung cancer, where early detection significantly improves survival rates. Cancer biomarkers also play a crucial role in monitoring treatment response. For example, biomarkers can be used to assess how well a patient is responding to chemotherapy, immunotherapy, or targeted therapies. In addition, they are used to detect minimal residual disease (MRD) after treatment, helping to identify early signs of relapse. Another important application is in prognostication, where biomarkers can provide insights into the likely progression of the disease, allowing for more informed decisions about treatment options. Personalized cancer therapies, which are designed to target specific mutations or molecular characteristics of the tumor, rely heavily on the identification of cancer biomarkers to select the most appropriate treatment for each patient.

Key Points

Cancer biomarkers provide critical information for the early detection, diagnosis, and monitoring of cancer.

Biomarkers enable personalized treatment approaches based on the genetic and molecular characteristics of both the patient and the tumor.

Liquid biopsy techniques are transforming cancer diagnosis and monitoring by providing non-invasive methods for detecting biomarkers in blood and other bodily fluids.

Multi-omics approaches that integrate genomic, proteomic, and metabolomic data are enhancing the discovery of new biomarkers.

AI and machine learning are improving the speed and accuracy of biomarker analysis, leading to better clinical outcomes.

Cancer biomarkers are used for early detection, treatment monitoring, and prognostication, with applications in personalized cancer therapies and companion diagnostics.

Conclusion

The role of cancer biomarkers in revolutionizing oncology cannot be overstated. As research continues to uncover new biomarkers and refine existing ones, the ability to detect cancer earlier, personalize treatments, and monitor disease progression will continue to improve. Liquid biopsies, multi-omics approaches, and the integration of artificial intelligence will further enhance the accuracy and accessibility of biomarker-based cancer diagnostics. The future of cancer treatment will increasingly rely on these biomarkers, leading to more effective, personalized therapies and better outcomes for patients. With continued innovation and collaboration, cancer biomarkers hold the potential to transform the landscape of cancer care, offering hope for earlier diagnoses, more effective treatments, and ultimately, improved survival rates.

Read More Details: https://www.snsinsider.com/reports/cancer-biomarkers-market-3324 

Contact Us:

Akash Anand — Head of Business Development & Strategy

Email: info@snsinsider.com

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND) 

[healthcaremarketanalysis]

Liquid Biopsy Market worth $11.3 billion by 2029

Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new report by MarketsandMarkets™.

In recent years, there has been substantial growth in the liquid biopsy market. The increasing burden of cancer cases globally has highlighted the urgent requirement for more effective and less invasive diagnostic tools. In this context, liquid biopsy emerges as a highly valuable solution. Unlike traditional tissue biopsies, which often involve invasive procedures and can be associated with discomfort and risks for patients, liquid biopsy offers a non-invasive alternative for detecting and monitoring cancer. Furthermore, these tests can also be used in non-invasive prenatal testing and transplantation medicine. Thus, these advantages are driving the rapid evolution and uptake of liquid biopsy products and services in disease diagnosis, treatment, and monitoring.

Liquid Biopsy Market Trends

Download an Illustrative overview:

Browse in-depth TOC on "Liquid Biopsy Market"

406 - Tables

56 - Figures

343 - Pages

In 2023, the assay kits segment held the largest share of the liquid biopsy market by product & service segment.

Based on product & service, the liquid biopsy market has been segmented into assay kits, instruments, and services. The assay kits segment dominated the liquid biopsy market in 2023. The versatility of assay kits contributes to their market dominance. These kits are adaptable to various biomarkers and analytes, accommodating the diverse needs of liquid biopsy applications, from detecting circulating tumor DNA (ctDNA) to monitoring treatment response and disease progression.

The therapy selection segment held the largest share of the liquid biopsy market by clinical application segment in 2023.

Based on clinical applications, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring.  In 2023, the largest share of the liquid biopsy market was held by the therapy selection segment. The growth of therapy selection as the major clinical application segment is fueled by the advantages of liquid biopsy over traditional methods with its minimally invasive, real-time monitoring capabilities across various cancer types, its integration into clinical trials and drug development processes, and its cost-effectiveness in guiding therapy selection.

North America is the largest regional market for liquid biopsy market.

The market for liquid biopsy has been divided into six key geographical regions, namely North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2023, North America held the predominant portion of the liquid biopsy market. The region boasts a well-developed healthcare infrastructure, including advanced diagnostic facilities, specialized oncology centers, and a skilled workforce. This infrastructure supports the integration of liquid biopsy into routine clinical practice, facilitating access for patients across various healthcare settings.

Request Sample Pages:

Liquid Biopsy Market Dynamics:

Drivers:

Rising incidence and prevalence of cancer

Cancer awareness initiatives undertaken by global health organizations

Benefits of liquid biopsy over traditional biopsy procedures

Restraints:

Lower sensitivity of certain liquid biopsy procedures

Opportunities:

Growing significance of companion diagnostics

Growth opportunities in emerging countries

Challenge:

Unclear reimbursement scenario

Key Market Players of Liquid Biopsy Industry:

The major players operating in this market are Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Guardant Health (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), Biocept, In. (US), mdxhealth (US), Personalis, Inc. (US), NeoGenomics Laboratories (US), Epigenomics AG (Germany), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Laboratory Corporation of America Holdings (US), Freenome Holdings, Inc. (US), Strand (India), LungLife AI, Inc. (US), and Lucence Health Inc. (US).

The break-up of the profile of primary participants in the liquid biopsy market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%

Get 10% Free Customization on this Report:

Recent Developments of Liquid Biopsy Industry:

In February 2024, Myriad Genetics, Inc. (US) entered into a definitive agreement to acquire select assets from Intermountain Health. These included assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory.

In January 2024, Natera, Inc. (US) acquired certain assets relating to non-invasive prenatal and carrier screening business from Invitae (US).

In November 2023, Illumina, Inc. (US) launched its TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2.

In April 2023, QIAGEN (Netherlands) launched the QIAseq Targeted cfDNA Ultra Panels, enabling researchers studying cancer and other diseases to turn cell-free DNA (cfDNA) liquid-biopsy samples into libraries ready for NGS in less than eight hours.

In January 2022, Illumina, Inc. (US) partnered with Boehringer Ingelheim (Germany). This partnership was aimed to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

Liquid Biopsy Market - Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall liquid biopsy market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Rising incidence and prevalence of cancer, cancer awareness initiatives undertaken by global health organizations, and increased benefits of liquid biopsy over traditional biopsy procedures), opportunities (Growing significance of companion diagnostics and growth opportunities in emerging countries), restraints (Lower sensitivity of certain liquid biopsy procedures), and challenges (Unclear reimbursement scenario) influencing the growth of the liquid biopsy market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.

Market Development: Comprehensive information about lucrative markets – the report analyses the liquid biopsy market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the liquid biopsy market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and F. Hoffmann-La Roche Ltd (Switzerland).

[health-views-updates]

MicroRNA  Market Size, Share & Industry Growth Outlook 2024-2032

The latest report by SNS Insider on the global MicroRNA Market presents in-depth insights into current market dynamics, trends, and growth prospects. According to the report, the MicroRNA Market is experiencing unprecedented expansion, attributed to its increasing applications in therapeutic and diagnostic fields. With a keen focus on RNA-based treatments for cancer, cardiovascular, and neurological disorders, the sector is poised to see substantial growth over the forecast period. MicroRNA Market Revenue is expected to reach new heights, influenced by ongoing research and development activities and a strong pipeline of microRNA-targeting drugs.

MicroRNA (miRNA) is a small, non-coding RNA molecule playing a critical role in gene expression regulation. Recent studies highlight the therapeutic potential of microRNAs in controlling disease progression by targeting specific genes. With the increase in personalized medicine and precision diagnostics, demand for miRNA-based interventions is rapidly rising. Pharmaceutical companies and research organizations are heavily investing in microRNA technology to harness its potential for diagnostic and therapeutic applications, particularly in oncology, which is witnessing promising results in disease suppression and early detection.

The report further reveals that major industry players are actively developing innovative solutions for miRNA sequencing, analysis, and delivery. This push is anticipated to stimulate a growth surge as miRNA technology finds new applications across diverse medical domains, from infectious disease management to regenerative medicine. Governments across the globe are supporting these initiatives by providing funding and regulatory clearances, further contributing to the market’s optimistic outlook.

Get Free Sample Report @ https://www.snsinsider.com/sample-request/3143

Key Market Highlights

Rising Applications in Therapeutics MicroRNA-based therapies offer high specificity in targeting disease mechanisms, especially in cancers and chronic diseases. By precisely modulating gene expression, miRNA-based drugs show potential in reducing adverse side effects and enhancing treatment outcomes. With regulatory bodies supporting clinical trials for miRNA-based treatments, the market is witnessing accelerated growth.

Advanced Diagnostic Applications The role of microRNAs in non-invasive diagnostics is gaining traction, especially for early-stage cancer detection and monitoring. miRNAs are emerging as valuable biomarkers, providing accurate diagnostic information with minimal invasiveness. Leveraging miRNAs in liquid biopsies and molecular diagnostics is creating a new frontier in healthcare diagnostics, with more personalized and predictive healthcare solutions.

Technological Innovations Driving Market Growth Innovations in miRNA analysis tools, sequencing platforms, and delivery systems are catalyzing the market’s expansion. Cutting-edge technologies such as CRISPR and RNA interference (RNAi) are being integrated with miRNA research, allowing precise genetic interventions. Such technological advancements are enabling faster, more accurate miRNA analysis, reducing costs and broadening accessibility.

Regional Insights

The report also highlights geographical trends, with North America holding a substantial share of the MicroRNA Market due to high R&D expenditure, a robust healthcare infrastructure, and increased awareness of personalized medicine. Meanwhile, the Asia-Pacific region is expected to register the highest growth rate, driven by increasing government funding, growing healthcare investments, and rising prevalence of chronic diseases. The region’s focus on adopting advanced therapeutic technologies is further boosting market opportunities.

Future Outlook

Looking ahead, the MicroRNA Market is set to benefit from continuous innovations and an expanding scope of applications. As the healthcare sector increasingly embraces miRNA-based therapies and diagnostics, significant investments are anticipated from both public and private sectors. Collaborations among biotechnology firms, academic institutions, and healthcare providers will be essential in advancing research and bringing miRNA-based solutions to mainstream healthcare.

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Akash Anand – Head of Business Development & Strategy info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[marketdevelopment]

Liquid Biopsy Market Size-Share, Growth Factors, Forecast 2023-2030

The Global Liquid Biopsy Market size is expected to grow from USD 1.59 billion in 2022 to USD 7.02 billion by 2030, at a CAGR of 20.4% during the forecast period (2023-2030).

The liquid biopsy market has been witnessing significant growth due to its non-invasive nature and its potential to revolutionize cancer diagnostics and treatment monitoring. Liquid biopsy involves the analysis of biomarkers, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes, extracted from bodily fluids like blood and urine. Traditional tissue biopsies are invasive and often provide limited information about tumor heterogeneity, making liquid biopsy an attractive alternative for cancer detection and monitoring.

Factors driving the growth of the liquid biopsy market include advancements in genomic technologies, increasing prevalence of cancer worldwide, rising demand for personalized medicine, and growing awareness about the benefits of early cancer detection. Additionally, the liquid biopsy market is propelled by ongoing research and development activities aimed at enhancing the sensitivity and specificity of liquid biopsy tests, as well as expanding their applications beyond cancer diagnosis to areas such as prenatal testing and organ transplantation monitoring.

Request Sample Copy@:

https://introspectivemarketresearch.com/request/16300

Updated Version 2024 is available our Sample Report May Includes the:

Scope For 2024

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Worldwide Market Reports 

Moreover, the report includes significant chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis which help to understand the market direction and movement in the current and upcoming years. 

Leading Key Players Covered Liquid Biopsy Market: -

F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (the US), Guardant Health Inc. (the US), BIOCEPT Inc. (the US), Illumina Inc. (the US), Angle plc (UK), Oncimmune(UK), Lucence health Inc. (US), FreenomeHoldings Inc. (US) and Other Major Players.

Segmentation of Liquid Biopsy Market: -

By Cancer Type         

By Circulating Biomarker     

By End-User   

Market Segment by Regions: -

North America (US, Canada, Mexico)

Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

South America (Brazil, Argentina, Rest of SA)

If You Have Any Queries Regarding Liquid Biopsy Market, Please Visit:

https://introspectivemarketresearch.com/inquiry/16300

Owning our reports (For More, Buy Our Report) will help you solve the following issues:

1. Uncertainty about the future?

Our research and insights help our clients to foresee upcoming revenue pockets and growth areas. This helps our clients to invest or divest their resources.

2. Understanding market sentiments?

It is imperative to have a fair understanding of market sentiments for a strategy. Our insights furnish you with a hawk-eye view on market sentiment. We keep this observation by engaging with Key Opinion Leaders of a value chain of each industry we track.

3. Understanding the most reliable investment centers?

Our research ranks investment centers of the market by considering their returns, future demands, and profit margins. Our clients can focus on the most prominent investment centers by procuring our market research.

4. Evaluating potential business partners?

Our research and insights help our clients in identifying compatible business partners.

Acquire This Report: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16300

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to helping our clients grow and successfully impact the marketplace. Our team at IMR is ready to help our clients grow their businesses by offering strategies to achieve success and monopoly in their respective fields. We are a global market research company, specializing in the use of big data and advanced analytics to gain a broader picture of market trends. We help our customers to think differently and build a better tomorrow for all of us. As a technology-driven research company, we consider extremely large data sets to uncover deeper insights and provide conclusive consulting. We don't just provide intelligence solutions, we help our clients achieve their goals.

Contact us:

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1049

Email: sales@introspectivemarketresearch.com